Investment marks continued progress against AbbVie's $100 billion commitment to U.S. R&D and capital investments, including manufacturing, over the next decade
The product will target Type 2 diabetes management aligning with unmet needs in India’s expanding metabolic care landscape
UBT251 appeared to have a safe and well-tolerated profile consistent with incretin-based therapies
The trial targeted a patient population with high BMI and extensive skin involvement, averaging over 39 kg/m²
Wegovy is now offered in six weekly doses in the EU: 0.25 mg, 0.5 mg, 1.0 mg, 1.7 mg, 2.4 mg, and the newly approved 7.2 mg dose
The pharmaceutical giant said it would pursue legal and regulatory action following Hims & Hers
Operating profit fell 1% in Danish kroner to DKK 127.7 billion but rose 6% at constant exchange rates
US revenue increased 43% to $12.9 billion, fueled by a 50% jump in volume, partially offset by a 7% decline in realized prices
Company to launch product after the expiry of semaglutide patent in India
Galenicum will oversee development, manufacturing and supply, while Lupin will handle regulatory submissions, approvals, and commercialization and distribution of Semaglutide across 23 countries globally
Subscribe To Our Newsletter & Stay Updated
